Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (14077)	12/27/2005 7:11:55 PM
From: Sergio H	Respond to of 23958

Sheesh, I guess I can't read dates on press releases. LOL! PMD feature in Forbes was two weeks ago, not today. This is from Ramsley (Walrus Partners): <Our New Selection is Psychemedics ( ASE - PMD $11.75 ). The company is a leading provider of drug testing services used primarily for pre-employment screening. Earnings are on the rise due to an improving job market. The company's unique technology also is likely to be approved in 2006 for use in broader applications, expanding the potential market. Earnings are on track to reach $.75 a share this year (+39%). Next year $.90 a share (+20%) represents a realistic target. If the Federal workplace market becomes available to the company a significantly better showing is possible. Our 2-3 year projection assumes that approval will occur. Earnings could reach $1.50 a share. Applying a P/E multiple of 20x suggests a target price of $30 a share, potential appreciation of more than 150% from the current quote. Meantime, Psychemedics pays a solid cash dividend of $.40 a share. >